AllSci News
Eli Lilly and Profluent form USD 2.25b partnership on AI-designed recombinases for genetic meds
Emeryville, California-based Profluent and Indianapolis-based Eli Lilly and Company (NYSE: LLY) have announced a multi-program strategic research collaboration to design and commercialize…
J&J’s Caplyta gets new US indication to prevent relapse in schizophrenia
Johnson & Johnson announced that the US FDA has approved a supplemental New Drug Application (sNDA) for Caplyta (lumateperone) for the prevention…
Remepy, Merck KGaA collaborate on hybrid drugs combined with AI-personalized digital therapeutics
Remepy, a New York-based digital health startup, has entered a hybrid drugs collaboration with Merck KGaA (FRA: MRK.DE; OTC: MKKGY), Darmstadt, Germany, to...
Taiho's first ADC enters clinic with Araris platform, targeting CD79b in non-Hodgkin lymphoma
Taiho Oncology and Araris Biotech AG have announced that the FDA has completed its Investigational New Drug review for ARC-02, a CD79b-targeting...
SOLVE FSHD awards grants to Radboud, Newcastle universities for FSHD biomarker validation
SOLVE FSHD has awarded approximately USD 571,000 across two projects through its 2025 Request for Proposals, directing the funds toward biomarker validation...
Janux discontinues EGFR-targeted TRACTr JANX008 after insufficient patient responses
Janux Therapeutics (San Diego, USA) announced the discontinuation of its JANX008 clinical development program, an EGFR-targeted Tumor Activated T Cell...
Roche's Q1'26 Earnings Call: Obesity dual agonist advances as giredestrant filed in adjuvant setting
Roche's Q1 2026 earnings conference call, held April 23, 2026, centered on three converging pipeline signals: an imminent fenebrutinib NDA filing carrying...
Oruka Therapeutics' ORKA-001 achieves 63.5% complete skin clearance in plaque psoriasis trial
Oruka Therapeutics reported Week 16 interim results from the EVERLAST-A Phase 2a trial of ORKA-001, a half-life extended IL-23p19 monoclonal antibody, in...
MSIDS Research Foundation and Hudson Valley Healing Arts Center report Alzheimer's biomarker normalization with dapsone therapy
MSIDS Research Foundation reports Alzheimer's biomarker normalization in chronic Lyme disease patient treated with dapsone combination therapy in Journal of...
Revolution Med starts patent spat over Erasca’s pan-RAS molecular glue ERAS-0015
Erasca, Inc. (USA) announced on April 27, 2026, via a US Securities and Exchange Commission Form 8-K filing, that Revolution Medicines, Inc.…
Sanofi's Q1'26 Earnings Call Highlights: Lunsekimig a new respiratory priority, amlitelimab safety profile defended
Sanofi signaled a strategic pivot toward lunsekimig as its next respiratory franchise asset while defending amlitelimab's path to regulatory submission...
Compass Therapeutics' tovecimig meets progression-free survival endpoint in Phase II/III biliary tract cancer trial
Compass Therapeutics (Nasdaq: CMPX) reported that tovecimig, its DLL4/VEGF-A bispecific antibody, met the key secondary endpoint of progression-free...
Novartis withdraws EMA application to expand Pluvicto into earlier prostate cancer setting
Novartis Withdraws EMA Application to Expand Pluvicto into Earlier Prostate Cancer Setting
Alltrna puts engineered tRNA therapeutic into first-in-human study
Alltrna, a Cambridge, Massachusetts-based Flagship Pioneering company, has received approval from Australia's Therapeutic Goods Administration to initiate a...
J&J’s anti-FcRn mAb Imaavy takes FDA Priority Review for wAIHA
Johnson & Johnson (NYSE: JNJ) announced receipt of US FDA Priority Review for the supplemental Biologics License Application (sBLA) for Imaavy (nipocalimab-aahu),…
The AllSci Brief
Systematic R&D and deal news. Daily.